CRSP icon

CRISPR Therapeutics
CRSP

Overview Fund Activity

395 hedge funds and large institutions have $2.45B invested in CRISPR Therapeutics in 2022 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 117 increasing their positions, 120 reducing their positions, and 87 closing their positions.

Holders
395
Holders Change
-39
Holders Change %
-8.99%
% of All Funds
6.37%
Holding in Top 10
3
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-62.5%
% of All Funds
0.05%
New
56
Increased
117
Reduced
120
Closed
87
Calls
$109M
Puts
$86.2M
Net Calls
+$23.2M
Net Calls Change
+$12.7M

Top Buyers

1
T. Rowe Price Investment Management
1
T. Rowe Price Investment Management
Maryland
$122M
2
State Street
2
State Street
Massachusetts
$84.6M
3
BlackRock
3
BlackRock
New York
$107M
4
Barclays
4
Barclays
United Kingdom
$15.8M
5
PI
5
PEAK6 Investments
Illinois
$11.1M

Top Sellers

1
AWA
1
Arete Wealth Advisors
Illinois
$230M
2
Bank of America
2
Bank of America
North Carolina
$17.3M
3
Macquarie Group
3
Macquarie Group
Australia
$1.62M
4
AIM
4
ARK Investment Management
Florida
$318M
5
IHAM
5
Integral Health Asset Management
New York
$0
Name Market Value Shares Shares
Change 		Shares
Change %
AIM
1
ARK Investment Management
Florida
$318M 7,829,932 -407,190 -5%
AWA
2
Arete Wealth Advisors
Illinois
$230M 5,661 -2,160 -28%
Capital International Investors
3
Capital International Investors
California
$218M 5,354,550 +12,132 +0.2%
Sumitomo Mitsui Trust Group
4
Sumitomo Mitsui Trust Group
Japan
$163M 4,006,476 -256,260 -6%
NAMA
5
Nikko Asset Management Americas
New York
$163M 4,006,476 -256,260 -6%
T. Rowe Price Investment Management
6
T. Rowe Price Investment Management
Maryland
$122M 2,993,577 +752,132 +34%
BlackRock
7
BlackRock
New York
$107M 2,629,737 +283,153 +12%
Fidelity Investments
8
Fidelity Investments
Massachusetts
$88.8M 2,184,384 +37,940 +2%
State Street
9
State Street
Massachusetts
$84.6M 2,081,116 +512,732 +33%
NMC
10
NEA Management Company
Maryland
$64.5M 1,587,854 -2,148 -0.1%
Vanguard Group
11
Vanguard Group
Pennsylvania
$58.6M 1,442,277 +6,867 +0.5%
Loomis, Sayles & Company
12
Loomis, Sayles & Company
Massachusetts
$48.3M 1,188,321 -56,878 -5%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$45.6M 1,122,848 -64,614 -5%
AC
14
Armistice Capital
New York
$42.1M 1,036,000 +112,000 +12%
BG
15
Bellevue Group
Switzerland
$37.1M 911,705 -16,600 -2%
CS
16
Credit Suisse
Switzerland
$34.7M 852,889 +12,183 +1%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$32.1M 789,098 +24,422 +3%
Renaissance Technologies
18
Renaissance Technologies
New York
$32M 786,600 +193,300 +33%
Norges Bank
19
Norges Bank
Norway
$29.1M 715,428 +48,660 +7%
Charles Schwab
20
Charles Schwab
California
$26.1M 641,094 +18,976 +3%
JPMorgan Chase & Co
21
JPMorgan Chase & Co
New York
$24M 589,623 -23,267 -4%
Federated Hermes
22
Federated Hermes
Pennsylvania
$20.7M 508,758 – –
Morgan Stanley
23
Morgan Stanley
New York
$20.6M 507,793 -78,051 -13%
VVM
24
Versant Venture Management
California
$20.3M 498,558 – –
Goldman Sachs
25
Goldman Sachs
New York
$20.2M 497,233 -248,673 -33%
1
2 3 4 5